Entacapone

What is Entacapone?

Entacapone is a pharmaceutical compound classified as a selective and reversible catechol-O-methyltransferase (COMT) inhibitor. It is primarily used in the management of Parkinson's disease, a neurodegenerative disorder characterized by motor symptoms like tremor, rigidity, and bradykinesia. Entacapone works by preventing the breakdown of levodopa, a precursor to dopamine, thereby increasing its availability to the brain and extending its therapeutic effect.

This medication is not used alone but as an adjunct to levodopa and carbidopa therapy. It is particularly beneficial for patients experiencing "wearing-off" phenomena, where levodopa's benefits diminish between doses, leading to a return of Parkinsonian symptoms. Entacapone falls under the Anatomical Therapeutic Chemical (ATC) classification system code N04, which designates drugs for Parkinsonism.

Mechanism of Action

Parkinson's disease involves a dopamine deficiency in the brain. Levodopa is administered to replenish dopamine, but it is extensively metabolized both peripherally and centrally. The enzyme catechol-O-methyltransferase (COMT) is a key enzyme that metabolizes levodopa into an inactive compound, 3-O-methyldopa (3-OMD), before it can cross the blood-brain barrier and convert to dopamine.

• Entacapone selectively inhibits the COMT enzyme, primarily in the periphery.
• By blocking COMT, Entacapone reduces the peripheral metabolism of levodopa.
• This action allows a greater proportion of levodopa to reach the central nervous system.
• Once in the brain, levodopa converts to dopamine, alleviating Parkinson's motor symptoms.
• The overall effect is an increased plasma half-life of levodopa, leading to more sustained dopaminergic stimulation and reduced motor fluctuations.

Medical Uses

Primary Uses

• Adjunctive therapy to levodopa and carbidopa in Parkinson's disease patients experiencing "wearing-off" phenomena.
• To reduce "off" periods and extend "on" time for patients with significant motor fluctuations despite optimized levodopa therapy.

Secondary Considerations

• May allow for a reduction in the total daily dose of levodopa in some patients, under strict medical supervision.
• Aims to improve overall motor control and quality of life by stabilizing levodopa plasma concentrations.

Dosage

The dosage of Entacapone is individualized based on patient response and tolerance. It is always taken with levodopa/carbidopa and guided by a healthcare professional.

Side Effects

Like all medications, Entacapone can cause side effects, many related to increased dopaminergic activity from enhanced levodopa effects, requiring careful monitoring.

Common Side Effects (may affect more than 1 in 10 people)

• Dyskinesia (involuntary movements, new onset or increase)
• Nausea, vomiting, abdominal pain, diarrhea (can be severe)
• Urine discoloration (reddish-brown, harmless)
• Dizziness, lightheadedness, orthostatic hypotension
• Insomnia, vivid dreams, hallucinations

Less Common or Serious Side Effects (may affect up to 1 in 100 people or less)

• Severe diarrhea leading to significant weight loss/dehydration.
• Rhabdomyolysis (muscle breakdown, rare but serious).
• Neuroleptic Malignant Syndrome (NMS)-like symptoms, especially upon abrupt withdrawal.
• Liver enzyme elevation.
• Impulse control disorders (e.g., pathological gambling, increased libido).

Warnings

Before initiating Entacapone, patients should be thoroughly evaluated. Healthcare providers must be aware of potential contraindications and precautions for patient safety.

Contraindications

• Hypersensitivity to Entacapone or its components.
• Pheochromocytoma, due to risk of hypertensive crisis.
• History of neuroleptic malignant syndrome (NMS) or non-traumatic rhabdomyolysis.
• Severe hepatic impairment, due to extensive liver metabolism.
• Concurrent use with non-selective monoamine oxidase (MAO) inhibitors (e.g., phenelzine) due to severe hypertensive reaction risk. Selective MAO-B inhibitors (e.g., selegiline) can generally be used cautiously.

Monitor patients for orthostatic hypotension, worsening dyskinesia, and impulse control disorders. Abrupt discontinuation of Entacapone should be avoided, as it can precipitate NMS-like symptoms or severe worsening of Parkinsonian symptoms. Levodopa dose adjustments may be necessary upon initiation.

Disclaimer: This medical information article is for educational purposes only and not a substitute for professional medical advice. Always consult your physician for diagnosis and treatment. Do not disregard professional medical advice or delay seeking it because of this article. Information provided may not cover all uses, directions, precautions, warnings, drug interactions, allergic reactions, or adverse effects.